With abortion access restricted across the U.S., a new diagnostic aims to eliminate birth control's pain points

The Latest

• 

  #DIA2022: Building 'guardrails' in the FDA's accelerated approval program

  Regulatory experts weigh in on ways to enhance the controversial drug approval approach.

  Patient

• 

  Podcast

  Woman of the Week: Kronos Bio's Barbara Kosacz

  Deal-maker, mentor and biotech industry mover and shaker, the COO and general counsel brings her 'smiling tiger' skills to her new role at the emerging company.

  Biotech

• 

  #DIA2022: How the industry's top regulator views the future of healthcare

  In the evolution of healthcare, data is the linchpin to making drug development more efficient.

  Biotech

• 

  The public health sleuth

  In her decades-long career, Mary Pittman, CEO of the Public Health Institute, has seen — and helped solve — one public health mystery after another.

  Leadership

• 

  Q&A

  Biotech spotlight: Karuna Therapeutics' mission to rejuvenate the field of neuroscience

  An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.

  Biotech

• 

  A patient-funded ALS drug offers hope where few treatments exist

  Eledon Pharmaceuticals’ grassroots-backed drug recently entered clinical trials.

  Biotech

• 

  TikTok tutorial: How pharma can embrace the video platform's educational potential

  Ogilvy Health’s director of social strategy, Katie Ferrigno, busts myths and provides tips on how biopharmas can take advantage of TikTok’s unique features to connect with patients.

  Commercialization

• 

  Podcast

  Woman of the Week: Tango Therapeutics' Dr. Barbara Weber

  A pioneer in genetic medicine, Dr. Barbara Weber continues to push the envelope to expand the reach of therapies based on genetic targeting.

  Biotech

• 

  Profile

  Buoyed by COVID-19 shot, J&J's vaccines head sees a new golden age approaching

  Janssen’s goal to have ‘a vaccine for the world’ is part of what drew Penny Heaton to the company and its work.

  Leadership

• 

  Q&A

  Why biomanufacturing is the next innovation frontier for genomic therapies

  While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.

  Biotech

• 

  Q&A

  First 90 Days: Editas Medicine's Gilmore O'Neill

  The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.

  Biotech

• 

  Making moves: Civica, Astellas, Inozyme and more announce key new hires

  The latest hiring moves from Civica, Astella, Inozyme and the Flagship Pioneering-founded Tessera Therapeutics. 

  Biotech

• 

  Q&A

  A combo of precision meds and diagnostics could disrupt mental healthcare

  HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.

  Biotech

• 

  As cancer innovations thrive, patient access is the next piece of the puzzle

  Why enhanced clinical trials and diagnostics are keys to boosting patient access to cancer care.

  Leadership

• 

  Podcast

  Woman of the Week: Janssen's Najat Khan

  Janssen’s Najat Khan, Ph.D., chief data science officer and global head of strategy and operations, shares how the company is using next-gen tech to ‘reimagine’ medicine.

  Leadership

• 

  Pharma giants take on Appalachian cancer rates in newest screening initiative

  AstraZeneca and Bristol Myers Squibb are teaming up with the nonprofit Association of Community Cancer Centers to increase lung cancer screening in rural Appalachia for the long haul.

  Patient

• 

  Profile

  After losing her daughter to a rare disease, Sharon King is looking to rewrite the playbook of drug development

  The communications pro is lending her community-building, storytelling expertise to the Bespoke Gene Therapy Consortium.

  Leadership

• 

  How to build a cancer pipeline: Big Pharma oncology heads on driving science forward

  Executives leading the cancer departments at J&J, Merck and Takeda chime in on what it takes to construct a successful and sustainable oncology drug pipeline.

  Leadership

• 

  Q&A

  First 90 Days: Janssen Immunology's David Jimenez

  The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.

  Biotech

• 

  Aduhelm's Medicare woes leave questions about lofty premiums

  A single drug’s effect on the premiums that Medicare beneficiaries pay is raising questions about how these levels are set and what factors play a part.

  Commercialization

• 

  Profile

  Flagship's creative approach to finding the next big idea in biopharma

  Avak Kahvejian, partner at Flagship Pioneering, a company that conceives, creates and launches bioplatform companies like Moderna, discusses its latest venture, ProFound Therapeutics.

  Biotech

• 

  Cell and gene therapy advances coming fast and furious

  A peek into R&D at the Mass General Brigham network reveals up-and-coming treatments pushing the boundaries of what’s possible in medicine.

  Biotech

• 

  Podcast

  Woman of the Week: OcuTerra Therapeutics' Kerrie Brady

  The serial entrepreneur and now head of OcuTerra explains why taking risks in pharma pays off.

  Biotech

• 

  SIGA prepares to kick production for monkeypox treatment into high gear

  ‘We’re not bored,’ the company’s science chief says as SIGA Technologies looks to ramp up supplies of its therapeutic.

  Manufacturing

• 

  Q&A

  First 90 Days: Sosei Heptares' Chris Cargill

  The company’s new CEO is looking to drive growth through collaboration and transparency.

  Leadership